Most of us have had frustrations with Biota management, historic and present, and a perceived lack of business clout when it comes to license deals...
...however, there is no question that Biota is one of (and probably) the leading biotechs in this space - they have a perfect record with development of Zanamivir and Lani.
They have moved forward to the clinical stage of HRV without a license partner. I think based on Biota's partnering track record, that this is a master-stroke - rather than being screwed down on a licensing deal at this stage of the development cycle, they are obviously confident and therefore prepared to take HRV to the next stage, where as mentioned by others, the drug will be worth far more, at which time, we will have more negotiating power.
Biota management - I applaud you on this decision.
I'd rather the company spend $25m on taking HRV to the next level, then give away a 13 cent unfranked dividend, or give away the drug for peanuts.
All in all, this is a no brainer investment opportunity that could result in $100s millions return.
One other big bonus - it is orally administered!!!!
More upside for Biota holders who have a little patience.
hrv trial, page-17
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)